FI20075258A0 - Menetelmä integriiniinhibiittorirespondereiden seulomiseksi - Google Patents

Menetelmä integriiniinhibiittorirespondereiden seulomiseksi

Info

Publication number
FI20075258A0
FI20075258A0 FI20075258A FI20075258A FI20075258A0 FI 20075258 A0 FI20075258 A0 FI 20075258A0 FI 20075258 A FI20075258 A FI 20075258A FI 20075258 A FI20075258 A FI 20075258A FI 20075258 A0 FI20075258 A0 FI 20075258A0
Authority
FI
Finland
Prior art keywords
responders
selling
procedure
integrin inhibitors
blockade
Prior art date
Application number
FI20075258A
Other languages
English (en)
Swedish (sv)
Inventor
Anne Marjamaeki
Liisa Nissinen
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Priority to FI20075258A priority Critical patent/FI20075258A0/fi
Publication of FI20075258A0 publication Critical patent/FI20075258A0/fi
Priority to AU2008237804A priority patent/AU2008237804A1/en
Priority to EP08736844A priority patent/EP2140029A2/en
Priority to PCT/FI2008/050195 priority patent/WO2008125738A2/en
Priority to US12/596,292 priority patent/US20120052057A9/en
Priority to CA002683312A priority patent/CA2683312A1/en
Priority to JP2010503536A priority patent/JP2010527233A/ja
Priority to NZ580235A priority patent/NZ580235A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI20075258A 2007-04-17 2007-04-17 Menetelmä integriiniinhibiittorirespondereiden seulomiseksi FI20075258A0 (fi)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FI20075258A FI20075258A0 (fi) 2007-04-17 2007-04-17 Menetelmä integriiniinhibiittorirespondereiden seulomiseksi
AU2008237804A AU2008237804A1 (en) 2007-04-17 2008-04-16 A method for selecting responders to blockade of integrin receptors
EP08736844A EP2140029A2 (en) 2007-04-17 2008-04-16 A method for selecting responders to blockade of integrin receptors
PCT/FI2008/050195 WO2008125738A2 (en) 2007-04-17 2008-04-16 A method for selecting responders to blockade of integrin receptors
US12/596,292 US20120052057A9 (en) 2007-04-17 2008-04-16 method for selecting responders to blockade of integrin receptors
CA002683312A CA2683312A1 (en) 2007-04-17 2008-04-16 A method for selecting responders to blockade of integrin receptors
JP2010503536A JP2010527233A (ja) 2007-04-17 2008-04-16 インテグリン受容体の遮断に対する反応者の選別方法
NZ580235A NZ580235A (en) 2007-04-17 2008-04-16 A method for selecting responders to blockade of integrin receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20075258A FI20075258A0 (fi) 2007-04-17 2007-04-17 Menetelmä integriiniinhibiittorirespondereiden seulomiseksi

Publications (1)

Publication Number Publication Date
FI20075258A0 true FI20075258A0 (fi) 2007-04-17

Family

ID=38009911

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075258A FI20075258A0 (fi) 2007-04-17 2007-04-17 Menetelmä integriiniinhibiittorirespondereiden seulomiseksi

Country Status (8)

Country Link
US (1) US20120052057A9 (fi)
EP (1) EP2140029A2 (fi)
JP (1) JP2010527233A (fi)
AU (1) AU2008237804A1 (fi)
CA (1) CA2683312A1 (fi)
FI (1) FI20075258A0 (fi)
NZ (1) NZ580235A (fi)
WO (1) WO2008125738A2 (fi)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3023497A1 (en) * 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
WO2013155686A1 (zh) * 2012-04-18 2013-10-24 Wang Lemin 整合素β亚基在诊断静脉血栓栓塞中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
JP2004141112A (ja) * 2002-10-28 2004-05-20 Pharma Design Inc 2型糖尿病患者における動脈硬化に対する易罹患性の判定方法
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia

Also Published As

Publication number Publication date
CA2683312A1 (en) 2008-10-23
WO2008125738A3 (en) 2008-12-11
NZ580235A (en) 2011-03-31
WO2008125738A2 (en) 2008-10-23
AU2008237804A1 (en) 2008-10-23
US20110150859A1 (en) 2011-06-23
EP2140029A2 (en) 2010-01-06
WO2008125738A8 (en) 2009-07-30
US20120052057A9 (en) 2012-03-01
JP2010527233A (ja) 2010-08-12

Similar Documents

Publication Publication Date Title
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
LTPA2016030I1 (lt) Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
CY1118125T1 (el) Αναστολεις ιβατ για τη θεραπεια ηπατικων νοσων
MA32934B1 (fr) Combinaisons inhibitrices hsp90
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
IN2012DN03012A (fi)
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
EA201170227A1 (ru) Имидазолкарбоксамиды
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
EA200970816A1 (ru) Новая лекарственная форма